Moderna stock jumped as five-year data from its personalized cancer vaccine trial with Merck showed a 49% reduction in melanoma recurrence risk, boosting hopes for mRNA's future in oncology.
Arbutus Biopharma shares dropped 16% after losing European patent dispute with Moderna. The biotech plans to appeal the ruling that affects ongoing litigation.
Moderna stock jumps 14%, driven by European expansion plans and a new flu-Covid combo vaccine aiming for 2026 approval.
Wells Fargo upgrades Monte Rosa Therapeutics on 2026 catalysts, while Jefferies downgrades Generation Bio due to its pending acquisition by Xoma.
Moderna and Novavax shares drop 5-6% after FDA's vaccine chief links COVID-19 shots to 10 children's deaths and announces stricter vaccine approval standards.
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.
